ProPhase Labs, Inc. Payments to Acquire Marketable Securities
ProPhase Labs, Inc. (PRPH) reported Payments to Acquire Marketable Securities of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2025-04-01
- ProPhase Labs, Inc. payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00.
- ProPhase Labs, Inc. payments to acquire marketable securities for the quarter ending 2024-09-30 was $0.00.
- ProPhase Labs, Inc. payments to acquire marketable securities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. payments to acquire marketable securities for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. payments to acquire marketable securities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ProPhase Labs, Inc. payments to acquire marketable securities for fiscal 2023 was $3.82M, a 43.65% decline from fiscal 2022.
- ProPhase Labs, Inc. payments to acquire marketable securities for fiscal 2022 was $6.78M, a 68.52% decline from fiscal 2021.
- ProPhase Labs, Inc. payments to acquire marketable securities for fiscal 2021 was $21.53M, a 372.08% increase from fiscal 2020.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $0.00 10-K · filed 2025-04-01 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $3.82M derived: sum of 3 quarters · filed 2025-04-01 | $3.82M 10-K · filed 2025-04-01 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.82M derived: sum of 2 quarters · filed 2024-11-13 | $3.82M 10-Q · filed 2024-11-13 | $9.59M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $3.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.82M 10-Q · filed 2024-08-14 | $9.59M derived: sum of 3 quarters · filed 2024-08-14 | $9.99M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-12 | $5.77M derived: sum of 2 quarters · filed 2024-03-29 | $6.17M derived: sum of 3 quarters · filed 2024-03-29 | $6.57M derived: sum of 4 quarters · filed 2024-03-29 | |
| 2022-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $6.17M derived: sum of 2 quarters · filed 2024-03-29 | $6.57M derived: sum of 3 quarters · filed 2024-03-29 | $6.78M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $396.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $797.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.00M 10-Q · filed 2023-11-13 | $1.00M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $607.00K 10-Q · filed 2023-08-11 | $607.00K derived: sum of 3 quarters · filed 2023-08-11 | $5.29M derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $206.00K 10-Q · filed 2023-05-12 | $206.00K derived: sum of 2 quarters · filed 2023-05-12 | $4.89M derived: sum of 3 quarters · filed 2023-05-12 | $19.73M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $4.69M derived: sum of 2 quarters · filed 2023-03-29 | $19.52M derived: sum of 3 quarters · filed 2023-03-29 | $21.53M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $4.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $19.52M derived: sum of 2 quarters · filed 2022-11-10 | $21.53M 10-Q · filed 2022-11-10 | $21.77M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $14.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $16.84M 10-Q · filed 2022-08-12 | $17.08M derived: sum of 3 quarters · filed 2022-08-12 | $17.96M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-13 | $2.25M derived: sum of 2 quarters · filed 2022-05-13 | $3.13M derived: sum of 3 quarters · filed 2022-05-13 | $5.86M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.12M derived: sum of 2 quarters · filed 2022-03-31 | $3.85M derived: sum of 3 quarters · filed 2022-03-31 | $4.56M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $881.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $3.61M derived: sum of 2 quarters · filed 2021-11-12 | $4.32M 10-Q · filed 2021-11-12 | $6.06M derived: sum of 4 quarters · filed 2021-11-12 | |
| 2020-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $3.44M 10-Q · filed 2021-08-13 | $5.17M derived: sum of 3 quarters · filed 2021-08-13 | $5.28M derived: sum of 4 quarters · filed 2021-08-13 | |
| 2020-03-31 | $706.00K 10-Q · filed 2021-05-14 | $2.44M derived: sum of 2 quarters · filed 2021-05-14 | $2.54M derived: sum of 3 quarters · filed 2021-05-14 | ||
| 2019-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $1.84M derived: sum of 2 quarters · filed 2021-03-31 | $3.14M 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-19 | $1.40M 10-Q · filed 2020-11-19 | |||
| 2019-06-30 | $1.30M 10-Q · filed 2020-08-11 | ||||
| 2018-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $3.76M derived: sum of 2 quarters · filed 2020-03-26 | $7.59M derived: sum of 3 quarters · filed 2020-03-26 | $13.35M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $6.27M derived: sum of 2 quarters · filed 2019-11-12 | $12.03M 10-Q · filed 2019-11-12 | $11.53M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $9.59M 10-Q · filed 2019-08-12 | $9.09M derived: sum of 3 quarters · filed 2019-08-12 | ||
| 2018-03-31 | $5.76M 10-Q · filed 2019-05-14 | $5.76M 10-Q · filed 2018-05-15 | $5.26M derived: sum of 2 quarters · filed 2019-05-14 | ||
| 2017-12-31 | -$501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $31.69M 10-K · filed 2019-03-26 | |||
| 2017-09-30 | $32.19M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |